AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8619354 — intervention group
Group type: EXPERIMENTAL
Intervention: Iobitridol 300 mg I/ml
Number of subjects: 60
Study 8619354 — intervention group
Group type: COMPARATOR
Intervention: Iopromide 300 mg I/ml
Number of subjects: 60
Study 1953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily at bedtime (n = 15)
Number of subjects: 26
Study 1953212 — intervention group
Group type: COMPARATOR
Intervention: Probucol 500 mg twice daily (n = 11)
Number of subjects: 26
Study 7171967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy (for clinical stage I)
Number of subjects: 1022
Study 7171967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy (for clinical stage II)
Number of subjects: 1022
Study 7171967 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy (for clinical stage II)
Number of subjects: 1022
Study 31142272 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 78
Study 31142272 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 78
Study 31142272 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Person
Number of subjects: 78
Study 30186865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic implant site preparation (UISP)
Number of subjects: 48
Study 30186865 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instrumentation (control)
Number of subjects: 48
Study 27278250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for psychotic disorders (18 months of therapy including 60 hours of group therapy and 15 hours of individual therapy)
Number of subjects: 0
Study 27278250 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 24488700 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs treatment
Number of subjects: 290
Study 24488700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neuroendocrine factors
Number of subjects: 290
Study 22142278 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning (Week 5)
Number of subjects: 571
Study 22142278 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals with stronger intention and higher maintenance self-efficacy
Number of subjects: 571
Study 19453582 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + ketamine 0.5 mg.kg(‐1)
Number of subjects: 60
Study 19453582 — intervention group
Group type: COMPARATOR
Intervention: Propofol 0.5 mg.kg(‐1) + fentanyl 1 microg.kg(‐1) + same volume of %0.9 NaCl
Number of subjects: 60
Study 17444593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 100
Study 17444593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17444593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (after Week 12)
Number of subjects: 100
Study 17444593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after Week 12)
Number of subjects: 100
Study 17444593 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 100
Study 17444593 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab and placebo
Number of subjects: 100
Study 15265969 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (four cycles of doxorubicin 75 mg/m2, followed by a single cycle of intermediate-dose cyclophosphamide 4000 mg/m2 supported by filgrastim 300 microg/day for up to 10 days, followed by high-dose cyclophosphamide 6000 mg/m2 and thiotepa 800 mg/m2)
Number of subjects: 605
Study 15265969 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (four cycles of doxorubicin 75 mg/m2 followed by eight cycles of CMF: cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and 5-fluorouracil 600 mg/m2)
Number of subjects: 605
Study 12398998 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil (5-FU) and folinic acid (LV)
Number of subjects: 0
Study 12398998 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and folinic acid (LV)
Number of subjects: 0
Study 9534093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 6
Study 9534093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg)
Number of subjects: 6
Study 9534093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=6489) taught to order radiography according to the Ottawa ankle rules
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6288)
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospitals intervention group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Community hospitals control group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching hospitals intervention group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Teaching hospitals control group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency physicians intervention group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Emergency physicians control group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physicians intervention group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Family physicians control group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Housestaff intervention group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Housestaff control group
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (no radiography)
Number of subjects: 12777
Study 7663253 — intervention group
Group type: COMPARATOR
Intervention: Control group (with radiography)
Number of subjects: 12777
Study 7663253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 12777
Study 2486586 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural catheter placement within 72 hours from the time of admission to the ICU (Group 2)
Number of subjects: 28
Study 2486586 — intervention group
Group type: COMPARATOR
Intervention: Standard morphine parenteral analgesia (Group 1)
Number of subjects: 28
Study 1086422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscularly applied leucovorin
Number of subjects: 45
Study 1086422 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin-tablets
Number of subjects: 45
Study 30526692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg vitamin D3/d
Number of subjects: 43
Study 30526692 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 µg vitamin D3/d
Number of subjects: 43
Study 30526692 — intervention group
Group type: EXPERIMENTAL
Intervention: >85 µg vitamin D3/d
Number of subjects: 43
Study 30526692 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg vitamin D3/d
Number of subjects: 43
Study 30526692 — intervention group
Group type: EXPERIMENTAL
Intervention: 85 µg vitamin D3/d
Number of subjects: 43
Study 28601750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 24
Study 28601750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of three 5-minute cycles of forearm ischemia followed by reperfusion
Number of subjects: 86
Study 25075773 — intervention group
Group type: COMPARATOR
Intervention: Standard care without RIPC
Number of subjects: 86
Study 23848107 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (10 mg/day for 6 months)
Number of subjects: 24
Study 23848107 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study 21050679 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Number of subjects: 52
Study 21050679 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 52
Study 18993044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator with automated air-leak compensation system
Number of subjects: 14
Study 17471343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 198
Study 17471343 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 198
Study 12775929 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device
Number of subjects: 0
Study 12775929 — intervention group
Group type: COMPARATOR
Intervention: Normal sitting (without CPM device)
Number of subjects: 0
Study 10855680 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbohydrate‐electrolyte drink (1.45+/‐0.29 litres)
Number of subjects: 6
Study 10855680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carbohydrate‐electrolyte drink (3.12+/‐0.47 litres)
Number of subjects: 6
Study 10855680 — intervention group
Group type: COMPARATOR
Intervention: No drink
Number of subjects: 6
Study 9401795 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles counted via light microscopy
Number of subjects: 9
Study 9401795 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles in the very anterior part of the entorhinal cortex
Number of subjects: 9
Study 9401795 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibrillary tangles in the anterior part of the right entorhinal region
Number of subjects: 9
Study 9401795 — intervention group
Group type: EXPERIMENTAL
Intervention: No neurofibrillary changes visible
Number of subjects: 9
Study 8498867 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of varicocele (26 patients)
Number of subjects: 96
Study 8498867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerosation or embolization (12 patients)
Number of subjects: 96
Study 8498867 — intervention group
Group type: COMPARATOR
Intervention: No therapy (41 patients)
Number of subjects: 96
Study 8498867 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (surgical, sclerosation, embolization)
Number of subjects: 96
Study 2423826 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis
Number of subjects: 4606
Study 2423826 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 4606
Study 31273791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus serotype 2 (DENV2) identified through polymerase chain reaction and Sanger's sequencing
Number of subjects: 24807
Study 31273791 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of DENV2 isolates
Number of subjects: 24807
Study 29049235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fold-type respirator
Number of subjects: 30
Study 29049235 — intervention group
Group type: COMPARATOR
Intervention: Cup-type respirator
Number of subjects: 30
Study 29049235 — intervention group
Group type: COMPARATOR
Intervention: Valve-type respirator
Number of subjects: 30
Study 27250601 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l polyethylene glycol (PEG) in a single dose
Number of subjects: 380
Study 27250601 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l polyethylene glycol (PEG) split into 3 + 1 l
Number of subjects: 380
Study 27250601 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + ascorbic acid (PEGA) split into 1 + 1 l or 2 l
Number of subjects: 380
Study 27250601 — intervention group
Group type: COMPARATOR
Intervention: PEG and PEGA in similar regimens
Number of subjects: 380
Study 23799553 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 61
Study 23799553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 61
Study 22400970 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 276
Study 22400970 — intervention group
Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 276
Study 19322744 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/day (n=23)
Number of subjects: 40
Study 19322744 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=17)
Number of subjects: 40
Study 17911549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 17911549 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery angioplasty and stenting (CAS)
Number of subjects: 0
Study 12620950 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra‐articular infusion with 0.2% ropivacaine at 10 mL/hr for 48 hours
Number of subjects: 17
Study 12620950 — intervention group
Group type: COMPARATOR
Intervention: Continuous interscalene block with 0.2% ropivacaine at 10 mL/hr for 48 hours
Number of subjects: 17
Study 10946875 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum levels of insulin-like growth factor I (IGF-I)
Number of subjects: 665
Study 10946875 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor binding protein-3 (IGFBP-3)
Number of subjects: 665
Study 10946875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate volume
Number of subjects: 665
Study 8817135 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg every 6 hours postoperatively)
Number of subjects: 103
Study 8817135 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per hour i.v.)
Number of subjects: 103
Study 8817135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study 1486965 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SML; 50 micrograms b.i.d.)
Number of subjects: 96
Study 1486965 — intervention group
Group type: COMPARATOR
Intervention: Slow-release theophylline and ketotifen (TK; T 300 mg+K 1 mg b.i.d.)
Number of subjects: 96
Study 1486965 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SML)
Number of subjects: 96
Study 6363488 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.26 mg
Number of subjects: 8
Study 6363488 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 2.08 mg
Number of subjects: 8
Study 6363488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3764397 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg i.m.)
Number of subjects: 122
Study 3764397 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodonum (15 mg i.m.)
Number of subjects: 122
Study 30170854 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758
Study 30170854 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758
Study 28644114 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 717
Study 28644114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 25780074 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP by helmet
Number of subjects: 30
Study 25780074 — intervention group
Group type: COMPARATOR
Intervention: CPAP by mask
Number of subjects: 30
Study 23706700 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 255
Study 23706700 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 255
Study 23706700 — intervention group
Group type: COMPARATOR
Intervention: Biomicroscopy
Number of subjects: 255
Study 23706700 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between OCT and FA
Number of subjects: 255
Study 23706700 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular leakage (ML) presence
Number of subjects: 255
Study 23706700 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular thickening (MT) presence
Number of subjects: 255
Study 23706700 — intervention group
Group type: COMPARATOR
Intervention: Biomicroscopic evaluation
Number of subjects: 255
Study 23706700 — intervention group
Group type: EXPERIMENTAL
Intervention: Phakic eyes without cataract
Number of subjects: 255
Study 20939644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose of .100%
Number of subjects: 185
Study 20939644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose of .075%
Number of subjects: 185
Study 20939644 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose of .050%
Number of subjects: 185
Study 20939644 — intervention group
Group type: COMPARATOR
Intervention: Alcohol dose of .000%
Number of subjects: 185
Study 20939644 — intervention group
Group type: EXPERIMENTAL
Intervention: GoStop Impulsivity Paradigm
Number of subjects: 185
Study 18250972 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH activity ≤ 10%
Number of subjects: 65
Study 18250972 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH activity 10‐52%
Number of subjects: 65
Study 18250972 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with H. pylori
Number of subjects: 65
Study 18250972 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients
Number of subjects: 65
Study 18250972 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA testing
Number of subjects: 65
Study 18250972 — intervention group
Group type: COMPARATOR
Intervention: MBL concentration and MBL/MASP‐2 complex activity
Number of subjects: 65
Study 16790517 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² on day 1 and gemcitabine 1000 mg/m² on days 1 and 8 every 3 weeks (group A)
Number of subjects: 166
Study 16790517 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and pegylated liposomal doxorubicin 40 mg/m² on day 1 every 4 weeks (group B)
Number of subjects: 166
Study 16790517 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 166
Study 15035763 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol by nebulizer every 20 minutes up to 2 hours
Number of subjects: 50
Study 15035763 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler with spacer every 20 minutes up to 2 hours
Number of subjects: 50
Study 11099870 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) and oral medroxyprogesterone acetate
Number of subjects: 240
Study 11099870 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclic association of oestradiol valerate and cyproterone acetate
Number of subjects: 240
Study 9214139 — intervention group
Group type: EXPERIMENTAL
Intervention: Miprovit
Number of subjects: 90
Study 1606067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, adriamycin, and cisplatin (CAP)
Number of subjects: 83
Study 1606067 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, adriamycin, and vincristin (CAV)
Number of subjects: 83
Study 3885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 45
Study 3885202 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 45
Study 3885202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 30099933 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT-RW (polyphenol-rich red wine)
Number of subjects: 12
Study 30099933 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT-A (low polyphenol alcoholic beverage - vodka)
Number of subjects: 12
Study 30099933 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT-CON (water)
Number of subjects: 12
Study 30099933 — intervention group
Group type: COMPARATOR
Intervention: CON (low NO3- salad and water)
Number of subjects: 12
Study 27037435 — intervention group
Group type: EXPERIMENTAL
Intervention: Exsanguination
Number of subjects: 26
Study 27037435 — intervention group
Group type: COMPARATOR
Intervention: Elevation
Number of subjects: 26
Study 24636526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide with or without corticosteroids
Number of subjects: 85
Study 24636526 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 85
Study 22500920 — intervention group
Group type: EXPERIMENTAL
Intervention: Myfenax(®) (Teva)
Number of subjects: 43
Study 22500920 — intervention group
Group type: COMPARATOR
Intervention: CellCept(®) (Roche)
Number of subjects: 43
Study 22500920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Myfenax(®) and CellCept(®)
Number of subjects: 43
Study 20727522 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 supplementation (1.2g/day for 3 months)
Number of subjects: 25
Study 20727522 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 18480626 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine suppository 2 h before biopsy
Number of subjects: 100
Study 18480626 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg lidocaine suppository 1 h before biopsy
Number of subjects: 100
Study 18480626 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg lidocaine suppository 2 h before biopsy
Number of subjects: 100
Study 18480626 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic infiltration of 5 ml 2% lidocaine
Number of subjects: 100
Study 15630488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 39
Study 15630488 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 39
Study 12859158 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg for 5 weeks, then 100 mg for 5 weeks)
Number of subjects: 147
Study 12859158 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg after 5 weeks)
Number of subjects: 147
Study 12859158 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 147
Study 12859158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 10634658 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with chest radiography
Number of subjects: 0
Study 10634658 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening for lung cancer
Number of subjects: 0
Study 8611830 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of aminoglycosides
Number of subjects: 3091
Study 8611830 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily doses of aminoglycosides
Number of subjects: 3091